Abstract
Original language | English |
---|---|
Journal | Nat. Commun. |
Volume | 10 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- biological marker
- cell surface protein
- antineoplastic hormone agonists and antagonists
- estrogen receptor alpha
- estrogen receptor alpha, human
- transcriptome
- biomarker
- cancer
- cell
- disease treatment
- endocrine system
- genetic analysis
- RNA
- area under the curve
- Article
- breast cancer
- cell subpopulation
- circulating tumor cell
- controlled study
- copy number variation
- CYP19A1 gene
- fluorescence activated cell sorting
- gene
- gene amplification
- gene expression
- gene regulatory network
- genetic variability
- hormonal therapy
- human
- human cell
- immunofluorescence
- live cell imaging
- primary tumor
- RNA sequence
- single cell analysis
- solid malignant neoplasm
- tissue microarray
- transcriptomics
- blood
- breast
- breast tumor
- cell plasticity
- cytology
- drug effect
- drug resistance
- female
- gene expression regulation
- genetics
- intravital microscopy
- machine learning
- MCF-7 cell line
- metabolism
- multicellular spheroid
- mutation
- pathology
- tumor embolism
- Antineoplastic Agents, Hormonal
- Breast
- Breast Neoplasms
- Cell Plasticity
- Drug Resistance, Neoplasm
- Estrogen Receptor alpha
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Intravital Microscopy
- Machine Learning
- MCF-7 Cells
- Mutation
- Neoplastic Cells, Circulating
- RNA-Seq
- Single-Cell Analysis
- Spheroids, Cellular
- Transcriptome
Fingerprint
Dive into the research topics of 'Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy: Nature Communications'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy : Nature Communications. / Hong, S.P.; Chan, T.E.; Lombardo, Y. et al.
In: Nat. Commun., Vol. 10, No. 1, 2019.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
T2 - Nature Communications
AU - Hong, S.P.
AU - Chan, T.E.
AU - Lombardo, Y.
AU - Corleone, G.
AU - Rotmensz, N.
AU - Bravaccini, S.
AU - Rocca, A.
AU - Pruneri, G.
AU - McEwen, K.R.
AU - Coombes, R.C.
AU - Barozzi, I.
AU - Magnani, L.
N1 - Cited By :4 Export Date: 27 February 2020 Correspondence Address: Hong, S.P.; Department of Surgery and Cancer, Imperial College LondonUnited Kingdom; email: s.hong@imperial.ac.uk Chemicals/CAS: Antineoplastic Agents, Hormonal; Estrogen Receptor alpha; estrogen receptor alpha, human Funding details: Imperial College Healthcare Charity, 642691 Funding details: C46704/A23110, G53019 Funding details: National Research Foundation of Korea, NRF, NRF-2013R1A1A1011832, CRUK C37/A18784 Funding details: National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology Funding text 1: We want to acknowledge and thank all patients and their families for the support and for donating the research samples. The authors gratefully acknowledge infrastructure support from the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre and the National Institute for Health Research Imperial Biomedical Research Centre. L.M. was supported by a CRUK fellowship (C46704/A23110) and an Imperial Junior Fellowship (G53019). S.P.H. was supported by a Basic Science Research Program through the National Research Foundation of Korea (NRF-2013R1A1A1011832) and by a CRUK programme award (CRUK C37/A18784). I.B. was supported by CRUK funding (C46704/A23110) and by an Imperial College Research Fellowship. G.C. was supported by a Marie Skłodowska Curie Training Grant (642691, EpiPredict). The Imperial College Healthcare NHS Trust Tissue Bank provided tissue samples. Consent was collected at IEO and Imperial College (Project R15036) by the respective Tissue Banks. Other investigators may have received samples from these same tissues. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. References: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials (2011) Lancet, 378, pp. 771-784; Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials (2015) Lancet, 386, pp. 1341-1352; Asselain, B., Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) Lancet Oncol., 19, pp. 27-39; Pan, H., 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years (2017) N. Engl. J. Med., 377, pp. 1836-1846; Casasent, A.K., Multiclonal invasion in breast tumors identified by topographic single cell sequencing (2018) Cell, 172, pp. 205-217.e12. , COI: 1:CAS:528:DC%2BC1cXkslehsA%3D%3D; Yap, T.A., Gerlinger, M., Futreal, P.A., Pusztai, L., Swanton, C., Intratumor heterogeneity: seeing the wood for the trees (2012) Sci. Transl. Med., 4, p. 127ps10; Polyak, K., Heterogeneity in breast cancer (2011) J. Clin. Invest., 121, pp. 3786-3788. , COI: 1:CAS:528:DC%2BC3MXht12ht7vP; Turajlic, S., Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal (2018) Cell, 173, pp. 581-594.e12. , COI: 1:CAS:528:DC%2BC1cXnsFClsLY%3D; Jamal-Hanjani, M., Tracking the evolution of non–small-cell lung cancer (2017) N. Engl. J. Med., 376, pp. 2109-2121. , COI: 1:CAS:528:DC%2BC2sXhtlyksrvM; Xue, Y., An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer (2017) Nat. Med., 23, p. 929. , COI: 1:CAS:528:DC%2BC2sXhtFOru7nM; Nazarian, R., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation (2010) Nature, 468, pp. 973-977. , COI: 1:CAS:528:DC%2BC3cXhsVOrsbjI; Misale, S., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer (2012) Nature, 486, pp. 532-536. , COI: 1:CAS:528:DC%2BC38XpsVSrsb4%3D; Johnson, B.E., Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma (2014) Science, 343, pp. 189-193. , COI: 1:CAS:528:DC%2BC2cXktVyktQ%3D%3D; Robinson, D.R., Activating ESR1 mutations in hormone-resistant metastatic breast cancer (2013) Nat. Genet., 45, pp. 1446-1451. , COI: 1:CAS:528:DC%2BC3sXhslWju7%2FN; Magnani, L., Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer (2017) Nat. Genet., 49, pp. 444-450. , COI: 1:CAS:528:DC%2BC2sXhtlKjsr4%3D; Siegel, M.B., Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer (2018) J. Clin. Invest., 128, pp. 1371-1383; Clatot, F., Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor (2016) Oncotarget, 7, pp. 74448-74459; Kim, C., Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing (2018) Cell, 173, pp. 879-893.e13. , COI: 1:CAS:528:DC%2BC1cXotFejt74%3D; Tirosh, I., Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) Science, 352, pp. 189-196. , COI: 1:CAS:528:DC%2BC28XlsFSmurk%3D; Hinohara, K., Wu, H.-J., Vigneau, S., McDonald, T.O., Igarashi, K.J., Yamamoto, K.N., Madsen, T., Polyak, K., KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (2018) Cancer Cell, 34 (6); Patten, D.K., Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer (2018) Nat. Med., 24, pp. 1469-1480. , COI: 1:CAS:528:DC%2BC1cXhtlOis7rJ; Rambow, F., Toward minimal residual disease-directed therapy in melanoma (2018) Cell, 174, pp. 843-855.e19. , COI: 1:CAS:528:DC%2BC1cXhtlartrfI; Ebinger, S., Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia (2016) Cancer Cell, 30, pp. 849-862. , COI: 1:CAS:528:DC%2BC28XhvF2gtr3O; Sharma, S.V., A Chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations (2010) Cell, 141, pp. 69-80. , COI: 1:CAS:528:DC%2BC3cXlsVSgtb8%3D; Karaayvaz, M., Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (2018) Nat. Commun., 9; Shaffer, S.M., Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (2017) Nature, 546, pp. 431-435. , COI: 1:CAS:528:DC%2BC2sXpt1Oqtbo%3D; Nguyen, V.T.M., Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion (2015) Nat. Commun., 6. , COI: 1:CAS:528:DC%2BC2MXhvFWksL3I; Martin, L.-A., Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance (2017) Nat. Commun., 8; Martin, L.-A., An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition (2011) Steroids, 76, pp. 772-776. , COI: 1:CAS:528:DC%2BC3MXnsVCgsbc%3D; Pisco, A.O., Non-Darwinian dynamics in therapy-induced cancer drug resistance (2013) Nat. Commun., 4; Razavi, P., The genomic landscape of endocrine-resistant advanced breast cancers (2018) Cancer Cell, 34, pp. 427-438.e6. , COI: 1:CAS:528:DC%2BC1cXhs12ntLfM; Wu, Y., Tamayo, P., Zhang, K., Visualizing and interpreting single-cell gene expression datasets with similarity weighted nonnegative embedding (2018) Cell Syst., 7, pp. 656-666.e4. , COI: 1:CAS:528:DC%2BC1cXis1SqsL7L; Tang, D.G., Understanding cancer stem cell heterogeneity and plasticity (2012) Cell Res., 22, pp. 457-472. , COI: 1:CAS:528:DC%2BC38Xjt1Wjurw%3D; Brooks, M.D., Burness, M.L., Wicha, M.S., Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer (2015) Cell Stem Cell, 17, pp. 260-271. , COI: 1:CAS:528:DC%2BC2MXhtlylsb%2FO; Chaffer, C.L., Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity (2013) Cell, 154, pp. 61-74. , COI: 1:CAS:528:DC%2BC3sXhtVGrtb3P; Bausch-Fluck, D., A mass spectrometric-derived cell surface protein atlas (2015) PLoS ONE, 10; Chan, T.E., Stumpf, M.P.H., Babtie, A.C., Gene regulatory network inference from single-cell data using multivariate information measures (2017) Cell Syst., 5, pp. 251-267.e3. , COI: 1:CAS:528:DC%2BC2sXhsFOrsLnM; Liberzon, A., The molecular signatures database hallmark gene set collection (2015) Cell Syst., 1, pp. 417-425. , COI: 1:CAS:528:DC%2BC2sXhtFaltLc%3D; Aibar, S., SCENIC: single-cell regulatory network inference and clustering (2017) Nat. Methods, 14, pp. 1083-1086. , COI: 1:CAS:528:DC%2BC2sXhs1aitL7P; Grossman, R.L., Toward a shared vision for cancer genomic data (2016) N. Engl. J. Med., 375, pp. 1109-1112; Colleoni, M., Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V (2016) J. Clin. Oncol., 34, pp. 927-935. , COI: 1:CAS:528:DC%2BC2sXnvFOhtw%3D%3D; Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) Lancet, 365, pp. 1687-1717; Blows, F.M., Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies (2010) PLoS Med., 7; Aceto, N., Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis (2014) Cell, 158, pp. 1110-1122. , COI: 1:CAS:528:DC%2BC2cXhsV2jtLbL; Yu, M., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition (2013) Science, 339, pp. 580-584. , COI: 1:CAS:528:DC%2BC3sXhsFGku7o%3D; Magnani, L., (2018) SREBP1 Drives Krt80-Dependent Cytoskeletal Changes and Invasive Behavior in Endocrine Resistant ERα Breast Cancer, , https://doi.org/10.1101/380634; Lawson, D.A., Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells (2015) Nature, 526, pp. 131-135. , COI: 1:CAS:528:DC%2BC2MXhs1SitL%2FK; Puram, S.V., Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer (2017) Cell, 171, pp. 1611-1624.e24. , COI: 1:CAS:528:DC%2BC2sXhvFWms7nE; Torre, E., Rare cell detection by single-cell RNA sequencing as guided by single-molecule RNA FISH (2018) Cell Syst., 6, pp. 171-179.e5. , COI: 1:CAS:528:DC%2BC1cXjs1aksLc%3D; Butler, A., Hoffman, P., Smibert, P., Papalexi, E., Satija, R., Integrating single-cell transcriptomic data across different conditions, technologies, and species (2018) Nat. Biotechnol., 36, pp. 411-420. , COI: 1:CAS:528:DC%2BC1cXmslKrtL0%3D; Lin, Y., (2018) Evaluating Stably Expressed Genes in Single Cells, , https://doi.org/10.1101/229815; Lun, A.T.L., McCarthy, D.J., Marioni, J.C., A step-by-step workflow for low-level analysis of single-cell RNA-seq data with bioconductor (2016) F1000Research, 5, p. 2122. , PID: 27909575; Patel, A.P., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma (2014) Science, 344, pp. 1396-1401. , COI: 1:CAS:528:DC%2BC2cXpslygsL4%3D; Nguyen, Q.H., Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity (2018) Nat. Commun., 9; Durinck, S., Spellman, P.T., Birney, E., Huber, W., Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt (2009) Nat. Protoc., 4, pp. 1184-1191. , COI: 1:CAS:528:DC%2BD1MXpt12ksrk%3D; Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2 (2012) Nat. Methods, 9, pp. 357-359. , COI: 1:CAS:528:DC%2BC38Xjt1Oqt7c%3D; Li, H., The sequence alignment/map format and SAMtools (2009) Bioinformatics, 25, pp. 2078-2079; Talevich, E., Shain, A.H., Botton, T., Bastian, B.C., CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing (2016) PLoS Comput. Biol., 12; Finak, G., MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data (2015) Genome Biol., 16; Benjamini, Y., Hochberg, Y., Benjaminit, Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing (1995) J. Royal Statist. Soc. Series B (Methodological), 57, pp. 289-300; Sing, T., Sander, O., Beerenwinkel, N., Lengauer, T., ROCR: visualizing classifier performance in R (2005) Bioinformatics, 21, pp. 3940-3941. , COI: 1:CAS:528:DC%2BD2MXhtFWltr7P; Breiman, L., Random forests (2001) Mach. Learn, 45, pp. 5-32; Parker, J.S., Supervised risk predictor of breast cancer based on intrinsic subtypes (2009) J. Clin. Oncol., 27, pp. 1160-1167
PY - 2019
Y1 - 2019
N2 - Resistant tumours are thought to arise from the action of Darwinian selection on genetically heterogenous cancer cell populations. However, simple clonal selection is inadequate to describe the late relapses often characterising luminal breast cancers treated with endocrine therapy (ET), suggesting a more complex interplay between genetic and non-genetic factors. Here, we dissect the contributions of clonal genetic diversity and transcriptional plasticity during the early and late phases of ET at single-cell resolution. Using single-cell RNA-sequencing and imaging we disentangle the transcriptional variability of plastic cells and define a rare subpopulation of pre-adapted (PA) cells which undergoes further transcriptomic reprogramming and copy number changes to acquire full resistance. We find evidence for sub-clonal expression of a PA signature in primary tumours and for dominant expression in clustered circulating tumour cells. We propose a multi-step model for ET resistance development and advocate the use of stage-specific biomarkers. © 2019, The Author(s).
AB - Resistant tumours are thought to arise from the action of Darwinian selection on genetically heterogenous cancer cell populations. However, simple clonal selection is inadequate to describe the late relapses often characterising luminal breast cancers treated with endocrine therapy (ET), suggesting a more complex interplay between genetic and non-genetic factors. Here, we dissect the contributions of clonal genetic diversity and transcriptional plasticity during the early and late phases of ET at single-cell resolution. Using single-cell RNA-sequencing and imaging we disentangle the transcriptional variability of plastic cells and define a rare subpopulation of pre-adapted (PA) cells which undergoes further transcriptomic reprogramming and copy number changes to acquire full resistance. We find evidence for sub-clonal expression of a PA signature in primary tumours and for dominant expression in clustered circulating tumour cells. We propose a multi-step model for ET resistance development and advocate the use of stage-specific biomarkers. © 2019, The Author(s).
KW - biological marker
KW - cell surface protein
KW - antineoplastic hormone agonists and antagonists
KW - estrogen receptor alpha
KW - estrogen receptor alpha, human
KW - transcriptome
KW - biomarker
KW - cancer
KW - cell
KW - disease treatment
KW - endocrine system
KW - genetic analysis
KW - RNA
KW - area under the curve
KW - Article
KW - breast cancer
KW - cell subpopulation
KW - circulating tumor cell
KW - controlled study
KW - copy number variation
KW - CYP19A1 gene
KW - fluorescence activated cell sorting
KW - gene
KW - gene amplification
KW - gene expression
KW - gene regulatory network
KW - genetic variability
KW - hormonal therapy
KW - human
KW - human cell
KW - immunofluorescence
KW - live cell imaging
KW - primary tumor
KW - RNA sequence
KW - single cell analysis
KW - solid malignant neoplasm
KW - tissue microarray
KW - transcriptomics
KW - blood
KW - breast
KW - breast tumor
KW - cell plasticity
KW - cytology
KW - drug effect
KW - drug resistance
KW - female
KW - gene expression regulation
KW - genetics
KW - intravital microscopy
KW - machine learning
KW - MCF-7 cell line
KW - metabolism
KW - multicellular spheroid
KW - mutation
KW - pathology
KW - tumor embolism
KW - Antineoplastic Agents, Hormonal
KW - Breast
KW - Breast Neoplasms
KW - Cell Plasticity
KW - Drug Resistance, Neoplasm
KW - Estrogen Receptor alpha
KW - Female
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Intravital Microscopy
KW - Machine Learning
KW - MCF-7 Cells
KW - Mutation
KW - Neoplastic Cells, Circulating
KW - RNA-Seq
KW - Single-Cell Analysis
KW - Spheroids, Cellular
KW - Transcriptome
U2 - 10.1038/s41467-019-11721-9
DO - 10.1038/s41467-019-11721-9
M3 - Article
SN - 2041-1723
VL - 10
JO - Nat. Commun.
JF - Nat. Commun.
IS - 1
ER -